{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:16:57Z","timestamp":1790752617567,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.bcp.2017.02.020","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T17:30:21Z","timestamp":1488216621000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Targeted pharmacotherapies for defective ABC transporters"],"prefix":"10.1016","volume":"136","author":[{"given":"Virginie","family":"Vauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Housset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Falgui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bcp.2017.02.020_b0005","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.GR-1649R","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","article-title":"Human ATP-binding cassette (ABC) transporter family","volume":"3","author":"Vasiliou","year":"2009","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.bcp.2017.02.020_b0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.12703\/P7-14","article-title":"Structure and mechanism of ABC transporters","volume":"7","author":"Wilkens","year":"2015","journal-title":"F1000Prime Rep."},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.febslet.2005.11.040","article-title":"Membrane topology of human ABC proteins","volume":"580","author":"Tusnady","year":"2006","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1042\/BST20150139","article-title":"ABC transporter research: going strong 40 years on","volume":"43","author":"Theodoulou","year":"2015","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.bcp.2017.02.020_b0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"Shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0040","first-page":"5","article-title":"Classification of cystic fibrosis and related disorders","volume":"1","author":"Organization","year":"2002","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"10.1016\/j.bcp.2017.02.020_b0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.bcp.2017.02.020_b0050","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"issue":"4922","key":"10.1016\/j.bcp.2017.02.020_b0060","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.bcp.2017.02.020_b0065","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJM199506013322204","article-title":"Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens","volume":"332","author":"Chillon","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0070","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2017.02.020_b0075","doi-asserted-by":"crossref","first-page":"e1000155","DOI":"10.1371\/journal.pbio.1000155","article-title":"CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium","volume":"7","author":"Zhang","year":"2009","journal-title":"PLoS Biol."},{"issue":"10","key":"10.1016\/j.bcp.2017.02.020_b0080","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"10059","key":"10.1016\/j.bcp.2017.02.020_b0090","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2017.02.020_b0095","doi-asserted-by":"crossref","first-page":"i859","DOI":"10.1136\/bmj.i859","article-title":"New and emerging targeted therapies for cystic fibrosis","volume":"352","author":"Quon","year":"2016","journal-title":"BMJ"},{"issue":"6389","key":"10.1016\/j.bcp.2017.02.020_b0100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/358761a0","article-title":"Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive","volume":"358","author":"Denning","year":"1992","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1379\/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2","article-title":"Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein","volume":"1","author":"Brown","year":"1996","journal-title":"Cell Stress Chaperones"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1074\/jbc.271.2.635","article-title":"Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation","volume":"271","author":"Sato","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"2 Pt 1","key":"10.1016\/j.bcp.2017.02.020_b0115","doi-asserted-by":"crossref","first-page":"C599","DOI":"10.1152\/ajpcell.1998.275.2.C599","article-title":"Activation of DeltaF508 CFTR in an epithelial monolayer","volume":"275","author":"Bebok","year":"1998","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nm0502-485","article-title":"Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells","volume":"8","author":"Egan","year":"2002","journal-title":"Nat. Med."},{"issue":"5670","key":"10.1016\/j.bcp.2017.02.020_b0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1093941","article-title":"Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects","volume":"304","author":"Egan","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2004.10.070","article-title":"Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein","volume":"325","author":"Loo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"39","key":"10.1016\/j.bcp.2017.02.020_b0135","doi-asserted-by":"crossref","first-page":"40629","DOI":"10.1074\/jbc.M407308200","article-title":"Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models","volume":"279","author":"Song","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1165\/rcmb.2005-0286OC","article-title":"SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis","volume":"34","author":"Grubb","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2017.02.020_b0145","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.febslet.2006.03.010","article-title":"Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat","volume":"580","author":"Norez","year":"2006","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.bcp.2017.02.020_b0150","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1172\/JCI119788","article-title":"In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR","volume":"100","author":"Rubenstein","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0155","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcf.2011.12.004","article-title":"A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference","volume":"11","author":"Leonard","year":"2012","journal-title":"J. Cyst. Fibros."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.02.020_b0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"issue":"5993","key":"10.1016\/j.bcp.2017.02.020_b0170","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","article-title":"Peripheral protein quality control removes unfolded CFTR from the plasma membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"issue":"52","key":"10.1016\/j.bcp.2017.02.020_b0175","doi-asserted-by":"crossref","first-page":"43630","DOI":"10.1074\/jbc.M112.421172","article-title":"Reduced PDZ interactions of rescued DeltaF508CFTR increases its cell surface mobility","volume":"287","author":"Valentine","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2017.02.020_b0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fphar.2012.00175","article-title":"Pharmacological Correctors of Mutant CFTR Mistrafficking","volume":"3","author":"Pedemonte","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2017.02.020_b0185","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.bcp.2017.02.020_b0190","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1074\/jbc.M110.184267","article-title":"Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations","volume":"286","author":"Pedemonte","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2017.02.020_b0195","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"44","key":"10.1016\/j.bcp.2017.02.020_b0200","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J. Cyst. Fibros."},{"issue":"21","key":"10.1016\/j.bcp.2017.02.020_b0210","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bcp.2017.02.020_b0215","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2017.02.020_b0220","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","article-title":"Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial","volume":"1","author":"Davies","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0225","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2015.01.008","article-title":"Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States","volume":"15","author":"Taylor-Cousar","year":"2016","journal-title":"J. Cyst. Fibros."},{"issue":"46","key":"10.1016\/j.bcp.2017.02.020_b0230","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0235","doi-asserted-by":"crossref","first-page":"e00152","DOI":"10.1002\/prp2.152","article-title":"Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR","volume":"3","author":"Farinha","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.bcp.2017.02.020_b0250","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0255","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40348-016-0040-z","article-title":"Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis","volume":"3","author":"Esposito","year":"2016","journal-title":"Mol Cell Pediatr"},{"key":"10.1016\/j.bcp.2017.02.020_b0265","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fphys.2013.00386","article-title":"Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels","volume":"4","author":"Martin","year":"2013","journal-title":"Front. Physiol."},{"issue":"7","key":"10.1016\/j.bcp.2017.02.020_b0270","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1074\/jbc.M111.275438","article-title":"Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1\/ABCB4","volume":"287","author":"Gautherot","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0275","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/hep.22499","article-title":"Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0280","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hep.22683","article-title":"Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing","volume":"49","author":"Byrne","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bcp.2017.02.020_b0285","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1074\/jbc.M111.310409","article-title":"Mutation of Glu521 or Glu535 in cytoplasmic loop 5 causes differential misfolding in multiple domains of multidrug and organic anion transporter MRP1 (ABCC1)","volume":"287","author":"Iram","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0290","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.bbamem.2013.11.002","article-title":"Differential functional rescue of Lys(513) and Lys(516) processing mutants of MRP1 (ABCC1) by chemical chaperones reveals different domain-domain interactions of the transporter","volume":"1838","author":"Iram","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"31","key":"10.1016\/j.bcp.2017.02.020_b0295","doi-asserted-by":"crossref","first-page":"22207","DOI":"10.1074\/jbc.M113.476218","article-title":"Crucial role for phylogenetically conserved cytoplasmic loop 3 in ABCC4 protein expression","volume":"288","author":"Cheepala","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0300","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1074\/jbc.M312810200","article-title":"Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor","volume":"279","author":"Yan","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2017.02.020_b0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-8-11","article-title":"Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines","volume":"8","author":"Sampson","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0310","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.bbrc.2008.03.018","article-title":"The ABCA1 Q597R mutant undergoes trafficking from the ER upon ER stress","volume":"369","author":"Tanaka","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"45","key":"10.1016\/j.bcp.2017.02.020_b0315","doi-asserted-by":"crossref","first-page":"32622","DOI":"10.1074\/jbc.M113.498980","article-title":"Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70","volume":"288","author":"Kapoor","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0320","doi-asserted-by":"crossref","first-page":"e0150098","DOI":"10.1371\/journal.pone.0150098","article-title":"Functional rescue of trafficking-impaired ABCB4 mutants by chemical chaperones","volume":"11","author":"Gordo-Gilart","year":"2016","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0325","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0165-6147(00)01575-3","article-title":"Pharmacological chaperones: a new twist on receptor folding","volume":"21","author":"Morello","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0330","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1074\/jbc.272.2.709","article-title":"Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators","volume":"272","author":"Loo","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2017.02.020_b0335","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10863-005-9499-3","article-title":"Rescue of folding defects in ABC transporters using pharmacological chaperones","volume":"37","author":"Loo","year":"2005","journal-title":"J. Bioenerg. Biomembr."},{"issue":"24","key":"10.1016\/j.bcp.2017.02.020_b0340","doi-asserted-by":"crossref","first-page":"14671","DOI":"10.1074\/jbc.273.24.14671","article-title":"Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions","volume":"273","author":"Loo","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0345","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1006\/bbrc.1998.8823","article-title":"Nonylphenol ethoxylates, but not nonylphenol, are substrates of the human multidrug resistance P-glycoprotein","volume":"247","author":"Loo","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0350","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bcp.2014.10.006","article-title":"Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation","volume":"92","author":"Loo","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"27","key":"10.1016\/j.bcp.2017.02.020_b0355","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1016\/S0021-9258(17)46252-1","article-title":"Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells","volume":"265","author":"Tamai","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0360","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1124\/mol.106.029926","article-title":"Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones","volume":"71","author":"Wang","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0365","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1074\/jbc.M113.527804","article-title":"Locking intracellular helices 2 and 3 together inactivates human P-glycoprotein","volume":"289","author":"Loo","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0370","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.28300","article-title":"A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3","volume":"63","author":"Delaunay","year":"2016","journal-title":"Hepatology"},{"issue":"44","key":"10.1016\/j.bcp.2017.02.020_b0375","doi-asserted-by":"crossref","first-page":"33403","DOI":"10.1074\/jbc.M605195200","article-title":"Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex","volume":"281","author":"Yan","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2017.02.020_b0380","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2337\/db07-0150","article-title":"Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: identification and rescue","volume":"56","author":"Yan","year":"2007","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0385","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1074\/jbc.M807012200","article-title":"Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure","volume":"284","author":"Pratt","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"29","key":"10.1016\/j.bcp.2017.02.020_b0390","doi-asserted-by":"crossref","first-page":"20942","DOI":"10.1074\/jbc.M113.470948","article-title":"Carbamazepine as a novel small molecule corrector of trafficking-impaired ATP-sensitive potassium channels identified in congenital hyperinsulinism","volume":"288","author":"Chen","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0395","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.1074\/jbc.M114.634576","article-title":"Structurally distinct ligands rescue biogenesis defects of the KATP channel complex via a converging mechanism","volume":"290","author":"Devaraneni","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"42","key":"10.1016\/j.bcp.2017.02.020_b0400","doi-asserted-by":"crossref","first-page":"21971","DOI":"10.1074\/jbc.M116.749366","article-title":"Pharmacological Correction of Trafficking Defects in ATP-Sensitive Potassium Channels Caused by Sulfonylurea Receptor 1 Mutations","volume":"291","author":"Martin","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0405","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1073\/pnas.051499698","article-title":"Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy","volume":"98","author":"Cartier","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"38","key":"10.1016\/j.bcp.2017.02.020_b0410","doi-asserted-by":"crossref","first-page":"35947","DOI":"10.1074\/jbc.M104762200","article-title":"Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism","volume":"276","author":"Partridge","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2017.02.020_b0415","doi-asserted-by":"crossref","first-page":"17139","DOI":"10.1074\/jbc.M200363200","article-title":"Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels","volume":"277","author":"Taschenberger","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0420","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1210\/jc.2004-1233","article-title":"Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity","volume":"89","author":"Tornovsky","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0425","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2265.2007.02847.x","article-title":"Complex ABCC8 DNA variations in congenital hyperinsulinism: lessons from functional studies","volume":"67","author":"Muzyamba","year":"2007","journal-title":"Clin. Endocrinol."},{"issue":"14","key":"10.1016\/j.bcp.2017.02.020_b0430","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1158\/0008-5472.CAN-11-2008","article-title":"Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter","volume":"72","author":"Basseville","year":"2012","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0435","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ."},{"key":"10.1016\/j.bcp.2017.02.020_b0440","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy","author":"Calder","year":"2016","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2017.02.020_b0445","first-page":"1697","article-title":"2-phenylethanol and some of its amphiphilic derivatives as inhibitors of platelet aggregation. Structure-activity relationship","volume":"25","author":"Brossmer","year":"1975","journal-title":"Arzneimittel-Forschung"},{"issue":"8","key":"10.1016\/j.bcp.2017.02.020_b0450","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJM199208203270818","article-title":"Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate","volume":"327","author":"Dover","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0455","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199301143280202","article-title":"A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders","volume":"328","author":"Perrine","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0460","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM199609193351204","article-title":"Long-term treatment of girls with ornithine transcarbamylase deficiency","volume":"335","author":"Maestri","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0465","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1152\/physiolgenomics.00160.2003","article-title":"Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins","volume":"16","author":"Wright","year":"2004","journal-title":"Physiol. Genomics"},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0470","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1471-4159.2006.03782.x","article-title":"Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress","volume":"97","author":"Kubota","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2017.02.020_b0475","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biocel.2015.01.015","article-title":"The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis","volume":"61","author":"Kolb","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0480","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11591280-000000000-00000","article-title":"Clinical and experimental applications of sodium phenylbutyrate","volume":"11","author":"Iannitti","year":"2011","journal-title":"Drugs R&D"},{"issue":"19","key":"10.1016\/j.bcp.2017.02.020_b0485","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1093\/hmg\/dds247","article-title":"Activation of the stress proteome as a mechanism for small molecule therapeutics","volume":"21","author":"Brose","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0490","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1194\/jlr.M027193","article-title":"Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate","volume":"54","author":"Sorrenson","year":"2013","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0495","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2013.06.054","article-title":"Effects of the gout-causing Q141K polymorphism and a CFTR DeltaF508 mimicking mutation on the processing and stability of the ABCG2 protein","volume":"437","author":"Saranko","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"13","key":"10.1016\/j.bcp.2017.02.020_b0500","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1073\/pnas.1214530110","article-title":"Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules","volume":"110","author":"Woodward","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"14","key":"10.1016\/j.bcp.2017.02.020_b0505","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1074\/jbc.M507515200","article-title":"Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome","volume":"281","author":"Cheong","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0510","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1083\/jcb.200501036","article-title":"Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator","volume":"169","author":"Gondcaille","year":"2005","journal-title":"J. Cell Biol."},{"issue":"9","key":"10.1016\/j.bcp.2017.02.020_b0515","doi-asserted-by":"crossref","first-page":"e24738","DOI":"10.1371\/journal.pone.0024738","article-title":"Expression and in vivo rescue of human ABCC6 disease-causing mutants in mouse liver","volume":"6","author":"Le Saux","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0520","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/jid.2013.482","article-title":"Analysis of pseudoxanthoma elasticum-causing missense mutants of ABCC6 in vivo; pharmacological correction of the mislocalized proteins","volume":"134","author":"Pomozi","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.bcp.2017.02.020_b0525","doi-asserted-by":"crossref","first-page":"e00241","DOI":"10.1042\/BSR20150150","article-title":"Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences","volume":"35","author":"Haider","year":"2015","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0530","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V84.1.339.339","article-title":"Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate","volume":"84","author":"Dover","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0535","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00005176-200407000-00007","article-title":"Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study","volume":"39","author":"Teckman","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0540","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V85.1.43.bloodjournal85143","article-title":"Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial","volume":"85","author":"Collins","year":"1995","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0545","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","article-title":"Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate","volume":"6","author":"Zeitlin","year":"2002","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0550","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jhep.2012.04.017","article-title":"Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2","volume":"57","author":"Gonzales","year":"2012","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0555","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jpeds.2013.12.032","article-title":"Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2","volume":"164","author":"Naoi","year":"2014","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0560","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/hep.27767","article-title":"Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate","volume":"62","author":"Gonzales","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0565","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/mol.106.023994","article-title":"Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones","volume":"70","author":"Wang","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"32","key":"10.1016\/j.bcp.2017.02.020_b0570","doi-asserted-by":"crossref","first-page":"19743","DOI":"10.1074\/jbc.M115.647685","article-title":"Rescuing trafficking mutants of the ATP-binding cassette protein, ABCA4, with small molecule correctors as a treatment for Stargardt eye disease","volume":"290","author":"Sabirzhanova","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5988","key":"10.1016\/j.bcp.2017.02.020_b0575","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1126\/science.1190354","article-title":"An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis","volume":"329","author":"Hidvegi","year":"2010","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.bcp.2017.02.020_b0580","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1074\/jbc.R109.072181","article-title":"Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases","volume":"285","author":"Renna","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0585","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr Physiol"},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0590","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clinre.2014.03.001","article-title":"ABCB4: Insights from pathobiology into therapy","volume":"38","author":"Falguieres","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0595","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1053\/j.gastro.2011.07.042","article-title":"Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity","volume":"141","author":"Groen","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0600","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","article-title":"Liver disease associated with canalicular transport defects: current and future therapies","volume":"52","author":"Stapelbroek","year":"2010","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0605","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/path.3019","article-title":"Canalicular ABC transporters and liver disease","volume":"226","author":"Nicolaou","year":"2012","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0610","doi-asserted-by":"crossref","first-page":"C1709","DOI":"10.1152\/ajpcell.00327.2007","article-title":"Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep\/Abcb11) correlate with severity of cholestatic diseases","volume":"293","author":"Lam","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2017.02.020_b0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-4-1","article-title":"Progressive familial intrahepatic cholestasis","volume":"4","author":"Davit-Spraul","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2017.02.020_b0620","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S2210-7401(12)70018-9","article-title":"Progressive familial intrahepatic cholestasis","volume":"36","author":"Jacquemin","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"9","key":"10.1016\/j.bcp.2017.02.020_b0625","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1016\/j.bmc.2012.03.016","article-title":"Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2","volume":"20","author":"Misawa","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2017.02.020_b0630","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/hep.21630","article-title":"4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps","volume":"45","author":"Hayashi","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2017.02.020_b0635","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/mol.108.049288","article-title":"Short-chain ubiquitination is associated with the degradation rate of a cell-surface-resident bile salt export pump (BSEP\/ABCB11)","volume":"75","author":"Hayashi","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2017.02.020_b0640","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/hep.25591","article-title":"AP2 adaptor complex mediates bile salt export pump internalization and modulates its hepatocanalicular expression and transport function","volume":"55","author":"Hayashi","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0645","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hepr.12561","article-title":"Successful treatment with 4-phenylbutyrate in a patient with benign recurrent intrahepatic cholestasis type 2 refractory to biliary drainage and bilirubin absorption","volume":"46","author":"Hayashi","year":"2016","journal-title":"Hepatol. Res.: Off. J. Jpn. Soc.Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2017.02.020_b0650","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ped.12839","article-title":"Effects of 4-phenylbutyrate therapy in a preterm infant with cholestasis and liver fibrosis","volume":"58","author":"Ito","year":"2016","journal-title":"Pediatr. Int.: Off. J. Jpn. Pediatr. Soc."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0655","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/MPG.0000000000001082","article-title":"Possible phenylacetate hepatotoxicity during 4-phenylbutyrate therapy of Byler disease","volume":"62","author":"Shneider","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"8","key":"10.1016\/j.bcp.2017.02.020_b0660","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1177\/0091270010379810","article-title":"Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers","volume":"51","author":"Perrine","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2017.02.020_b0665","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.1002\/ajh.23533","article-title":"A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease","volume":"88","author":"Kutlar","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.bcp.2017.02.020_b0670","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1182\/blood-2013-11-538470","article-title":"A phase 2 trial of HQK-1001 in HbE-beta thalassemia demonstrates HbF induction and reduced anemia","volume":"123","author":"Patthamalai","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2017.02.020_b0675","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.23725","article-title":"A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease","volume":"89","author":"Reid","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2017.02.020_b0680","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2017.02.020_b0685","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.510250303","article-title":"Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis","volume":"25","author":"Jacquemin","year":"1997","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2017.02.020_b0690","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0695","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0030-1253223","article-title":"The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects","volume":"30","author":"Davit-Spraul","year":"2010","journal-title":"Semin. Liver Dis."},{"issue":"5","key":"10.1016\/j.bcp.2017.02.020_b0700","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/hep.26970","article-title":"Molecular mechanistic explanation for the spectrum of cholestatic disease caused by the S320F variant of ABCB4","volume":"59","author":"Andress","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2017.02.020_b0705","doi-asserted-by":"crossref","first-page":"26872","DOI":"10.1038\/srep26872","article-title":"Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3","volume":"6","author":"Park","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2017.02.020_b0710","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/hep.28929","article-title":"Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770)","volume":"65","author":"Delaunay","year":"2017","journal-title":"Hepatology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T18:07:15Z","timestamp":1658686035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217301120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":142,"alternative-id":["S0006295217301120"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.02.020","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted pharmacotherapies for defective ABC transporters","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}